The acquisition will expand Nexelis’ immunology testing expertise.
On March 4, 2020, Nexelis, a portfolio company of Ampersand Capital Partners and a provider of assay development and advanced laboratory testing, announced that it has signed a definitive agreement to acquire ImmunXperts, a Brussels, Belgium-based immunogenicity and immune-oncology testing laboratory. The transaction is expected to close by the end of March. Financial details of the deal were not disclosed.
ImmunXperts has developed and performs a full offering of immunogenicity and immuno-oncology in-vitro functional and potency assays, which help pharmaceutical and biotech sponsors screen, select, and optimize lead compounds before the initiation of in-vivo trials.
“ImmunXperts’ immunology testing expertise will help Nexelis more broadly serve the needs of our customers,” said Benoit Bouche, Nexelis president and CEO, in a company press release. “Nexelis will now have an unrivaled ability to efficiently develop immunogenicity assays, qualify and validate them in a regulated environment, and then ultimately perform them utilizing our high-throughput platforms in support of clinical trials.”
“We are proud of ImmunXperts’ achievements over the past five years and are grateful for the support obtained from our investors and partners, our employees, and the Wallonia region. We are excited to continue our growth trajectory as part of Nexelis and serve as a European hub for the company,” added Sofie Pattijn, chief technology officer, and Thibault Jonckheere, CEO, ImmunXperts, in the press release. Both Pattijn and Jonckheere will continue in senior leadership roles at Nexelis.
Source: Nexelis
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.